Literature DB >> 26365457

Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse.

D Funk1, S Lo2, K Coen3, A D Lê4.   

Abstract

Alcohol and nicotine (in the form of tobacco) are often taken together, with increased negative health consequences. Co-use may modify intake of one or both of the drugs, or the effects of drugs used to treat nicotine or alcohol addiction. Varenicline is commonly prescribed as an aid to enhance quitting smoking. More recently it has been shown to reduce alcohol intake in humans and laboratory animals. There is little work investigating the role of co-exposure to alcohol and nicotine in the effects of varenicline. In pilot clinical studies, it has been reported that smoking enhances varenicline's effectiveness as a treatment for alcohol misuse, but this relationship has not been systematically investigated. To help resolve this, we examined if the effects of varenicline on alcohol and nicotine self-administration (SA) in rats are modified when the two drugs are taken together. Rats were trained on alcohol SA, and some were implanted with i.v. catheters for nicotine SA. Groups of animals then lever pressed for alcohol or nicotine alone, and another group lever pressed for alcohol and nicotine, using a two lever choice procedure. Varenicline did not affect alcohol SA. Varenicline reduced nicotine SA modestly. Access to both alcohol and nicotine reduced self-administration of either drug, but did not change the effects of varenicline. We found that in rats with a history of alcohol SA, varenicline reduced reinstatement of extinguished alcohol seeking induced by exposure to an alcohol prime combined with cues previously associated with alcohol.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol; Cues; Nicotine; Reinstatement; Self-administration; Varenicline

Mesh:

Substances:

Year:  2015        PMID: 26365457      PMCID: PMC4659739          DOI: 10.1016/j.bbr.2015.09.009

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  46 in total

Review 1.  Nicotine addiction and comorbidity with alcohol abuse and mental illness.

Authors:  John A Dani; R Adron Harris
Journal:  Nat Neurosci       Date:  2005-11       Impact factor: 24.884

2.  Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Authors:  Hans Rollema; Mihály Hajós; Patricia A Seymour; Rouba Kozak; Mark J Majchrzak; Victor Guanowsky; Weldon E Horner; Doug S Chapin; William E Hoffmann; David E Johnson; Stafford McLean; Jody Freeman; Kathryn E Williams
Journal:  Biochem Pharmacol       Date:  2009-06-06       Impact factor: 5.858

3.  Matching law analysis of rats' alcohol self-administration in a free-operant choice procedure.

Authors:  Corina Jimenez-Gomez; Timothy A Shahan
Journal:  Behav Pharmacol       Date:  2008-07       Impact factor: 2.293

4.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

5.  alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.

Authors:  Brendan M Walker; Dennis D Rasmussen; Murray A Raskind; George F Koob
Journal:  Alcohol       Date:  2008-03       Impact factor: 2.405

6.  The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.

Authors:  Mia Ericson; Elin Löf; Rosita Stomberg; Bo Söderpalm
Journal:  J Pharmacol Exp Ther       Date:  2009-01-06       Impact factor: 4.030

7.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.

Authors:  Pia Steensland; Jeffrey A Simms; Joan Holgate; Jemma K Richards; Selena E Bartlett
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

8.  Varenicline reduces alcohol self-administration in heavy-drinking smokers.

Authors:  Sherry A McKee; Emily L R Harrison; Stephanie S O'Malley; Suchitra Krishnan-Sarin; Julia Shi; Jeanette M Tetrault; Marina R Picciotto; Ismene L Petrakis; Naralys Estevez; Erika Balchunas
Journal:  Biol Psychiatry       Date:  2009-02-27       Impact factor: 13.382

9.  Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.

Authors:  Andrea King; Dingcai Cao; Catherine Vanier; Tracie Wilcox
Journal:  Alcohol Clin Exp Res       Date:  2009-03-19       Impact factor: 3.455

Review 10.  Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors.

Authors:  Douglas Funk; Peter W Marinelli; Anh D Lê
Journal:  Alcohol Res Health       Date:  2006
View more
  21 in total

1.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

2.  Nicotine as a discriminative stimulus for ethanol use.

Authors:  Brett C Ginsburg; Simon A Levy; R J Lamb
Journal:  Drug Alcohol Depend       Date:  2017-11-21       Impact factor: 4.492

Review 3.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

Review 4.  The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Authors:  Matthew B Pomrenze; Tracy L Fetterly; Danny G Winder; Robert O Messing
Journal:  Alcohol Clin Exp Res       Date:  2017-10-25       Impact factor: 3.455

5.  Assessment of individual differences in response to acute bupropion or varenicline treatment using a long-access nicotine self-administration model and behavioral economics in female rats.

Authors:  Theodore Kazan; Christopher L Robison; Nicole Cova; Victoria M Madore; Sergios Charntikov
Journal:  Behav Brain Res       Date:  2020-02-25       Impact factor: 3.332

6.  The Effects of Long-Term Varenicline Administration on Ethanol and Sucrose Seeking and Self-Administration in Male P Rats.

Authors:  Cristine L Czachowski; Janice C Froehlich; Michael DeLory
Journal:  Alcohol Clin Exp Res       Date:  2017-12-23       Impact factor: 3.455

7.  Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.

Authors:  Cassie M Chandler; Sarah E Maggio; Hui Peng; Kimberly Nixon; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

Review 8.  The role of nicotinic acetylcholine receptors in alcohol-related behaviors.

Authors:  C N Miller; H M Kamens
Journal:  Brain Res Bull       Date:  2020-07-22       Impact factor: 4.077

9.  Development of a novel alcohol and nicotine concurrent access (ANCA) self-administration procedure in baboons.

Authors:  August F Holtyn; Catherine M Davis; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2019-11-11       Impact factor: 4.492

Review 10.  Mechanisms and genetic factors underlying co-use of nicotine and alcohol or other drugs of abuse.

Authors:  Sarah J Cross; Shahrdad Lotfipour; Frances M Leslie
Journal:  Am J Drug Alcohol Abuse       Date:  2016-08-17       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.